{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-030243","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.701739+00:00","generated_at":"2026-06-01T00:59:09.317676+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"X4 reports positive Phase 2 mavorixafor data in chronic neutropenia; starts Phase 3 4WARD trial","bullets":["100% (6/6) evaluable participants achieved target ANC increase (>500 cells/µL) at Months 3 and 6 on mavorixafor ± G-CSF.","Mavorixafor monotherapy achieved mean ANC ≥1,500 cells/µL at Months 3 and 6; severe CN patients had mean ANC ~800-1,000 cells/µL.","Combination with stable-dose G-CSF increased mean ANC >1,000 cells/µL vs baseline at Months 1, 3, and 6.","No drug-related serious adverse events; three discontinuations due to non-serious AEs.","Global Phase 3 4WARD trial initiated (randomized, 150 patients, 52 weeks) for congenital, autoimmune, or idiopathic CN."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-030243","json":"https://secwatch.observer/filing/0001628280-24-030243.json","markdown":"https://secwatch.observer/filing/0001628280-24-030243.md","text":"https://secwatch.observer/filing/0001628280-24-030243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024030243/0001628280-24-030243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024030243/xfor-20240627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:59:09.317676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}